Nanoparticles have the potential to drive completely new applications in molecular imaging, targeted therapy, and theranostics in human disease. Defined as specifically engineered particles that are 1 to 100 nm in at least 1 dimension, nanoparticles have been applied in clinical applications in cancer where they display improved sensitivity in detection of liver metastasis and better tissue characterization of colorectal lesions [@bib1]. Oncology has employed them due to their diverse multifunctionality (e.g., modification for localized therapy), high payload capacity, and targeting capability [@bib1], yet these state-of-the-art developments have yet to capture major attention in the cardiovascular disease (CVD) field.

HDL represents a promising "building block," which could form the basis of a successful CVD nanoparticle because: 1) they are naturally-occurring, circulate-freely, and are biocompatible/biodegradable [@bib1]; 2) they may be intrinsically therapeutic via their cholesterol efflux properties [@bib1], [@bib2], [@bib3]; 3) they may target inflammatory intraplaque macrophages and monocytes [@bib1], [@bib3]; and 4) they can be engineered to serve as "nanocarriers" for delivering both imaging and therapeutic payloads. However, HDL is not necessarily deliverable in sufficient quantities to every patient's plaque site(s).

In a new study in *JACC: Cardiovascular Imaging*, Pérez-Medina et al. [@bib4] advanced their pursuit of this target by generating a positron emission tomography (PET)-imageable HDL nanoparticle via incorporation of the radioisotope ^89^Zr. The team reconstituted synthetic discoidal HDL nanoparticles consisting of the primary constituents of HDL, apolipoprotein A-I (ApoA-I) and the phospholipid phosphocholine. Two differently radiolabeled HDL nanoparticles were developed, one in which the chelator for binding ^89^Zr was conjugated to ApoA-I and in the other, conjugated to phosphocholine. ^89^Zr-ApoA-I and phosphocholine-^89^Zr nanoparticles were used to validate delivery to atherosclerotic sites, quantify biodistributions, and identify which nanoparticle type better targets atherosclerotic plaques. For translation, the investigators employed 3 different animal models of atherosclerosis, all fed high fat diets---an *ApoE*^*−/−*^ murine model; a New Zealand white rabbit model with a double balloon injury of the thoracic and abdominal aorta; and a familial hypercholesterolemia porcine model with balloon injuries on the deep and superficial femoral arteries ([Central Illustration](#undfig1){ref-type="graphic"}).

In all the animal models, the target organs for HDL nanoparticles were identical, with the kidneys the primary accumulation site, but with consistent localization in atherosclerotic plaque, as well. In mice, atherosclerotic plaque uptake was significant only for phosphocholine-^89^Zr particles (p = 0.02) compared with wild-type controls with an ∼50% signal increase [@bib4]. In rabbits, plaques were targeted again only by phosphocholine-^89^Zr particles at ∼100% above control animals as quantified by PET. In pigs, phosphocholine-^89^Zr particles allowed visualization of atherosclerosis, with a trend of increased uptake in plaque, compared with controls.

In parallel with the PET studies, the authors employed fluorophore (DiR)-loaded HDL nanoparticles to show uptake into atherosclerotic macrophages and inflammatory monocytes in mice via flow cytometry. Macrophages and Ly-6C^hi^ monocytes took up HDL nanoparticles ∼3- to 4.5-fold over other plaque cells such as neutrophils [@bib4]. This may be insufficient to engender suitably large differences in signal when performing macroscopic imaging such as PET, consistent with the signal observed in the animal studies [@bib4]. This is likely related to HDL nanoparticle targeting, a function of their inability to penetrate deeply into plaques because: 1) atherosclerotic plaque permeability variation may preclude free apoA-I HDL from accessing advanced plaques [@bib2]; and 2) selective targeting in blood circulation is insufficient to enable cellular uptake (dendritic cells in blood were targeted more than Ly-6C^hi^ monocytes [@bib4]) and plaque penetration. However, the fact that those inflammatory cells that go on to become M1 macrophages and foam cells may be precisely targetable is an important finding that could allow for "Trojan Horse" treatment with deep penetration of the atherosclerotic plaque in the future [@bib5].

Translational Relevance {#sec1}
=======================

Although reduced HDL levels are unequivocally associated with increased risk for CVD, a number of studies suggest HDL may not be causal for CVD [@bib3]. These include sophisticated Mendelian randomization studies and several clinical trials that suggest raising HDL levels does not necessarily prevent heart attacks and strokes, thereby calling the "HDL hypothesis" into question. Instead, investigators are now focused on the "HDL flux hypothesis" and finding ways to deliver sufficient functional HDL (which may induce reverse cholesterol transport to macrophages) to diseased vessels. Yet HDL accumulation is notably complex compared with typical nanoparticles---instead of getting trapped, they recirculate through the lymph and display a relatively long half-life [@bib2]. HDL, therefore, does not accumulate in plaque, but reaches a steady state, and given clinical PET spatial resolutions (several millimeters), it can be challenging to spatially distinguish particles in the vessel wall compared with those in blood.

Nevertheless, molecular imaging approaches such as those shown here may be useful to help stratify patients and determine which ones will accumulate high levels of a desired therapy. "Pre-testing" using replica-reporter agents may be particularly desirable if the drug of interest is expensive or has side effects that one would wish to avoid in a "nonresponder." Additionally, nanoparticles such as modified HDL can be bioengineered to achieve enhanced therapeutic effect. For example, it may be that those subfractions of HDL that cause the largest increases in cholesterol efflux could be conjugated to the nanoparticles that accumulate in M1 macrophages. Modified theranostic nanoparticles (AGuIX, activation and guiding of irradiation by X-ray) are now being evaluated in French Phase 1 clinical trials for cancer imaging and radiotherapy (Radiosensitization of Multiple Brain Metastases Using AGuIX Gadolinium Based Nanoparticles \[NANO-RAD\]; [NCT02820454](https://clinicaltrials.gov/ct2/show/NCT02820454){#intref0010}). They home to brain metastases to sensitively detect (using magnetic resonance imaging) and deliver radiosensitization for radiation therapy. The hope is that similar advances will occur in the field of cardiovascular medicine, and allow targeted treatment of the vulnerable atherosclerotic plaque.
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